🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is Page 6

Can we talk about how SLOW the FDA is

KarenAZ_mom Mon, Apr 20, 2026 at 10:27 AM 38 replies 1,036 viewsPage 6 of 8
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
May 6, 2026 at 11:48 PM#26
pat_auckland said:
It is worth asking what the claim would look like if it were false.

There is a second half to this that has not been said yet. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: May 7, 2026 at 5:48 AM
50 0TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 47 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
May 9, 2026 at 2:01 AM#27

Adding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Last edited: May 9, 2026 at 5:01 AM
49 24AmyNC_wife, SkepticalSean, Dr.CardioMD and 46 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
May 11, 2026 at 4:13 AM#28

One thing that is still open after pat_auckland’s answer:

How would you tell the difference between that and the alternative explanation?

48 23TomTeleRx, DoseLogDan, SleepFixSam and 45 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
carlos_SATX
Member
245
1,123
Oct 2024
San Antonio, TX
May 13, 2026 at 6:24 AM#29
dan_philly said:
If you are going to change something, change one thing and give it long enough to express itself.

Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.

47 22LindaRN_retired, tommy_boulder, hyun_seoul and 44 others
Reply Quote Save Share Report
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
May 15, 2026 at 8:34 AM#30

OP back with an update, since a thread like this is useless without one.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

25 0HPLC_Greg, LibrarianMeg, bri_stats and 22 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register